New Cell Therapies
The use of new cell therapies has taken a major step forward in recent years. The need for a link between the basic sciences and the possibility of applying this research directly in the patient is the key to success. The use of Human Induced Pluripotent Pluripotent Stem Cells (hiPSCs) would make it possible to carry out personalized medicine, which allows tissue or organs to be generated from the patient's own cells, thus avoiding possible rejections or complications of immunosuppression strategies. Current studies aim to develop a specific humanized hiPSC pancreas in an apancreatic pig by complementing interspecific blastocyst. The clinical implications of this technique extend beyond experimental models. The objective of the current studies is not only to obtain a human pancreas in the porcine species, but also to obtain the organ that the patient needs. The CRISPR Cas9 system is only applied to cells that divide. But since November 2016, Dr. Izpisua's team has started to use a modification of the CRISPR Cas9 technique by means of the Homology Independent Targeted Integration (HITI) method, by which he has been able to introduce DNA in a specific location of the cell genome that does not divide. This has opened up new avenues for basic research and also for the treatment of monogenic diseases. GOAL: Know new cell therapies